Streptozotocin as a tool to induce central pathology and cognitive impairment in rodents

Streptozotocin: Uses, Mechanism of Action and Side Effects

Volumn , Issue , 2014, Pages 1-23

  Garcia Alloza, Monica ^a  

^a UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904901303     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (150)

1. Alvarez, E. O., Beauquis, J., Revsin, Y., Banzan, A. M., Roig, P., De Nicola, A. F. and Saravia, F. (2009) Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes. Behav Brain Res. 198, 224-230.
2. Artola, A., Kamal, A., Ramakers, G. M., Biessels, G. J. and Gispen, W. H. (2005) Diabetes mellitus concomitantly facilitates the induction of long-term depression and inhibits that of long-term potentiation in hippocampus. Eur. J. Neurosci. 22, 169-178.
3. Bhat, N. R. (2010) Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J. Neurochem. 115, 551-562.
4. Biessels, G. J., Kamal, A., Ramakers, G. M., Urban, I. J., Spruijt, B. M., Erkelens, D. W. and Gispen, W. H. (1996) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes. 45, 1259-1266.
5. Brendza, R. P., Bacskai, B. J., Cirrito, J. R. et al. (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115, 428-433.
6. Brookmeyer, R., Johnson, E., Ziegler-Graham, K. and Arrighi, H. M. (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186-191.
7. Brown, C. E., Aminoltejari, K., Erb, H., Winship, I. R. and Murphy, T. H. (2009) In vivo voltage-sensitive dye imaging in adult mice reveals that somatosensory maps lost to stroke are replaced over weeks by new structural and functional circuits with prolonged modes of activation within both the peri-infarct zone and distant sites. J. Neurosci. 29, 1719-1734.
8. Burke, M. C., Nelson, L., Slade, J. Y., Oakley, A. E., Khundakar, A. A. and Kalaria, R. N. (2013) Morphometry of the hippocampal microvasculature in post-stroke and age-related dementias. Neuropathol Appl Neurobiol.
9. Clodfelder-Miller, B. J., Zmijewska, A. A., Johnson, G. V. and Jope, R. S. (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes. 55, 3320-3325.
10. Comin, D., Gazarini, L., Zanoni, J. N., Milani, H. and de Oliveira, R. M. (2010) Vitamin E improves learning performance and changes the expression of nitric oxide-producing neurons in the brains of diabetic rats. Behav Brain Res. 210, 38-45.
11. Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I. and Smith, M. A. (2011) Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev. 10, 264-273.
12. Craft, S. (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 66, 300-305.
13. Craggs, L. J., Hagel, C., Kuhlenbaeumer, G. et al. (2013) Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases. Brain Pathol. 23, 547-557.
14. Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C. and He, L. (2013a) Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 1, CD008900.
15. Chen, Y., Liang, Z., Blanchard, J. et al. (2013b) A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol. Neurobiol. 47, 711-725.
16. Chen, Y., Liang, Z., Tian, Z., Blanchard, J., Dai, C. L., Chalbot, S., Iqbal, K., Liu, F. and Gong, C. X. (2013c) Intracerebroventricular Streptozotocin Exacerbates Alzheimer-Like Changes of 3xTg-AD Mice. Mol. Neurobiol.
17. Dalla, Y., Singh, N., Jaggi, A. S. and Singh, D. (2010) Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions. Pharmacol Rep. 62, 784-796.
18. de la Monte, S. M. and Wands, J. R. (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci Technol. 2, 1101-1113.
19. de Leeuw, F. E., de Groot, J. C., Oudkerk, M., Witteman, J. C., Hofman, A., van Gijn, J. and Breteler, M. M. (2002) Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 125, 765-772.
20. Devedjian, J. C., George, M., Casellas, A., Pujol, A., Visa, J., Pelegrin, M., Gros, L. and Bosch, F. (2000) Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J. Clin. Invest. 105, 731-740.
21. Devi, L., Alldred, M. J., Ginsberg, S. D. and Ohno, M. (2012) Mechanisms underlying insulin deficiency-induced acceleration of beta-amyloidosis in a mouse model of Alzheimer's disease. PLoS One. 7, e32792.
22. Dhull, D. K., Bhateja, D., Dhull, R. K. and Padi, S. S. (2012) Differential role of cyclooxygenase isozymes on neuronal density in hippocampus CA1 region of intracerebroventricular streptozotocin treated rat brain. J. Chem. Neuroanat. 43, 48-51.
23. Ding, Y., Zhang, Z., Dai, X., Jiang, Y., Bao, L. and Li, Y. (2013) Grape seed proanthocyanidins ameliorate pancreatic beta-cell dysfunction and death in low-dose streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats partially by regulating endoplasmic reticulum stress. Nutr. Metab (Lond). 10, 51.
24. Duelli, R., Schrock, H., Kuschinsky, W. and Hoyer, S. (1994) Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int. J. Dev. Neurosci. 12, 737-743.
25. Dumont, M. and Beal, M. F. (2011) Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol. Med. 51, 1014-1026.
26. Eckman, E. A. and Eckman, C. B. (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc Trans. 33, 1101-1105.
27. Ejaz Ahmed, M., Khan, M. M., Javed, H., Vaibhav, K., Khan, A., Tabassum, R., Ashafaq, M., Islam, F. and Safhi, M. M. (2013) Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Neurochem Int. 62, 492-501.
28. Farris, W., Mansourian, S., Chang, Y. et al. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA. 100, 4162-4167.
29. Flood, J. F., Mooradian, A. D. and Morley, J. E. (1990) Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes. 39, 1391-1398.
30. Frisoni, G. B., Fox, N. C., Jack, C. R., Jr., Scheltens, P. and Thompson, P. M. (2010) The clinical use of structural MRI in Alzheimer disease. Nat. Rev Neurol. 6, 67-77.
31. Frolich, L., Blum-Degen, D., Bernstein, H. G. et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. 105, 423-438.
32. Frydman-Marom, A., Levin, A., Farfara, D. et al. (2011) Orally administrated cinnamon extract reduces beta-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One. 6, e16564.
33. Garcia-Alloza, M., Borrelli, L. A., Hyman, B. T. and Bacskai, B. J. (2010) Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. Neurobiol Aging. 31, 2058-2068.
34. Garcia-Alloza, M., Dodwell, S. A., Meyer-Luehmann, M., Hyman, B. T. and Bacskai, B. J. (2006a) Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J. Neuropathol Exp. Neurol. 65, 1082-1089.
35. Garcia-Alloza, M., Prada, C., Lattarulo, C., Fine, S., Borrelli, L. A., Betensky, R., Greenberg, S. M., Frosch, M. P. and Bacskai, B. J. (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J. Neurochem. 109, 1636-1647.
36. Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X. et al. (2006b) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516-524.
37. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E. and Hyman, B. T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24.
38. Gong, C. X., Grundke-Iqbal, I. and Iqbal, K. (2010) Targeting tau protein in Alzheimer's disease. Drugs Aging. 27, 351-365.
39. Gorelick, P. B. (2004) Risk factors for vascular dementia and Alzheimer disease. Stroke. 35, 2620-2622.
40. Gorelick, P. B. and Nyenhuis, D. (2013) Understanding and treating vascular cognitive impairment. Continuum (Minneap Minn). 19, 425-437.
41. Gotz, J., Ittner, L. M. and Lim, Y. A. (2009) Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci. 66, 1321-1325.
42. Greenberg, S. M., Grabowski, T., Gurol, M. E. et al. (2008) Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol. 64, 587-591.
43. Grunblatt, E., Salkovic-Petrisic, M., Osmanovic, J., Riederer, P. and Hoyer, S. (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 101, 757-770.
44. Guglielmotto, M., Aragno, M., Tamagno, E. et al. (2012) AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging. 33, 196 e113-127.
45. Harman, D. (2006) Alzheimer's disease pathogenesis: role of aging. Ann N Y Acad Sci. 1067, 454-460.
46. He, Y., Zheng, M. M., Ma, Y., Han, X. J., Ma, X. Q., Qu, C. Q. and Du, Y. F. (2013) Soluble oligomers and fibrillar species of amyloid beta-peptide differentially affect cognitive functions and hippocampal inflammatory response. Biochem Biophys Res Commun. 429, 125-130.
47. Heo, J. H., Lee, S. R., Lee, S. T., Lee, K. M., Oh, J. H., Jang, D. P., Chang, K. T. and Cho, Z. H. (2011) Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. J. Alzheimers Dis. 25, 517-523.
48. Hiltunen, M., Khandelwal, V. K., Yaluri, N. et al. (2012) Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J. Cell Mol Med. 16, 1206-1222.
49. Honig, L. S., Kukull, W. and Mayeux, R. (2005) Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 64, 494-500.
50. Hoyer, S., Lannert, H., Noldner, M. and Chatterjee, S. S. (1999) Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J. Neural Transm. 106, 1171-1188.
51. Hoyer, S., Muller, D. and Plaschke, K. (1994) Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J. Neural Transm Suppl. 44, 259-268.
52. Hyman, B. T. (2011) Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 68, 1062-1064.
53. Hyman, B. T. and Gomez-Isla, T. (1996) Neuropathological markers of impaired cognition in the entorhinal cortex. Neurobiol Aging. 17, 940-941; discussion 945-947.
54. Hyman, B. T. and Trojanowski, J. Q. (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 56, 1095-1097.
55. Ishrat, T., Hoda, M. N., Khan, M. B., Yousuf, S., Ahmad, M., Khan, M. M., Ahmad, A. and Islam, F. (2009) Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol. 19, 636-647.
56. Ivan, C. S., Seshadri, S., Beiser, A., Au, R., Kase, C. S., Kelly-Hayes, M. and Wolf, P. A. (2004) Dementia after stroke: the Framingham Study. Stroke. 35, 1264-1268.
57. Jankowsky, J. L., Fadale, D. J., Anderson, J. et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 13, 159-170.
58. Jelinek, D., Millward, V., Birdi, A., Trouard, T. P., Heidenreich, R. A. and Garver, W. S. (2011) Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance. Hum. Mol Genet. 20, 312-321.
59. Jimenez-Palomares, M., Ramos-Rodriguez, J. J., Lopez-Acosta, J. F., Pacheco-Herrero, M., Lechuga-Sancho, A. M., Perdomo, G., Garcia-Alloza, M. and Cozar-Castellano, I. (2012) Increased Abeta production prompts the onset of glucose intolerance and insulin resistance. Am. J. Physiol Endocrinol Metab. 302, E1373-1380.
60. Jolivalt, C. G., Calcutt, N. A. and Masliah, E. (2012) Similar pattern of peripheral neuropathy in mouse models of type 1 diabetes and Alzheimer's disease. Neuroscience. 202, 405-412.
61. Jolivalt, C. G., Hurford, R., Lee, C. A., Dumaop, W., Rockenstein, E. and Masliah, E. (2010) Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp. Neurol. 223, 422-431.
62. Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A. and Masliah, E. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci Res. 86, 3265-3274.
63. Ke, Y. D., Delerue, F., Gladbach, A., Gotz, J. and Ittner, L. M. (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One. 4, e7917.
64. Knowles, R. B., Wyart, C., Buldyrev, S. V., Cruz, L., Urbanc, B., Hasselmo, M. E., Stanley, H. E. and Hyman, B. T. (1999) Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96, 5274-5279.
65. Konarkowska, B., Aitken, J. F., Kistler, J., Zhang, S. and Cooper, G. J. (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. Febs J. 273, 3614-3624.
66. Kraska, A., Santin, M. D., Dorieux, O. et al. (2012) In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One. 7, e46196.
67. Labak, M., Foniok, T., Kirk, D., Rushforth, D., Tomanek, B., Jasinski, A. and Grieb, P. (2010) Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir Suppl. 106, 177-181.
68. Lannert, H. and Hoyer, S. (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 1199-1208.
69. Larson, J., Lynch, G., Games, D. and Seubert, P. (1999) Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 840, 23-35.
70. Lee, M. S. (2013) Treatment of Autoimmune Diabetes by Inhibiting the Initial Event. Immune Netw. 13, 194-198.
71. Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R. and de la Monte, S. M. (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 9, 13-33.
72. Li, Y., Duffy, K. B., Ottinger, M. A. et al. (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19, 1205-1219.
73. Liu, P., Zou, L. B., Wang, L. H., Jiao, Q., Chi, T. Y., Ji, X. F. and Jin, G. (2013) Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats. Psychopharmacology (Berl).
74. Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J. and Hyman, B. T. (2003) Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23, 10879-10883.
75. Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S. and Mayeux, R. (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 65, 545-551.
76. Luchsinger, J. A., Tang, M. X., Shea, S. and Mayeux, R. (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology. 63, 1187-1192.
77. Matsuzaki, T., Sasaki, K., Tanizaki, Y. et al. (2010) Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 75, 764-770.
78. Matveyenko, A. V. and Butler, P. C. (2006) Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes. 55, 2106-2114.
79. Mehla, J., Pahuja, M. and Gupta, Y. K. (2013) Streptozotocin-induced sporadic Alzheimer's disease: selection of appropriate dose. J. Alzheimers Dis. 33, 17-21.
80. Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C. et al. (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 451, 720-724.
81. Moorhouse, P. and Rockwood, K. (2008) Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 7, 246-255.
82. Mukai, N., Hori, S. and Pomeroy, M. (1980) Cerebral lesions in rats with streptozotocin-induced diabetes. Acta Neuropathol. 51, 79-84.
83. Nugent, D. A., Smith, D. M. and Jones, H. B. (2008) A review of islet of Langerhans degeneration in rodent models of type 2 diabetes. Toxicol Pathol. 36, 529-551.
84. O'Brien, J. T. (2006) Vascular cognitive impairment. Am. J. Geriatr Psychiatry. 14, 724-733.
85. Orgogozo, J. M., Gilman, S., Dartigues, J. F. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 61, 46-54.
86. Ott, A., Stolk, R. P., Hofman, A., van Harskamp, F., Grobbee, D. E. and Breteler, M. M. (1996) Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 39, 1392-1397.
87. Pappolla, M. A. (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 71, 2020; author reply 2020-2021.
88. Pappolla, M. A., Bryant-Thomas, T. K., Herbert, D. et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 61, 199-205.
89. Park, S. A. (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J. Clin. Neurol. 7, 10-18.
90. Patel, B. M. and Bhadada, S. V. (2013) Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril. Clin. Exp. Hypertens.
91. Plaschke, K. and Hoyer, S. (1993) Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int. J. Dev. Neurosci. 11, 477-483.
92. Plaschke, K., Kopitz, J., Siegelin, M., Schliebs, R., Salkovic-Petrisic, M., Riederer, P. and Hoyer, S. (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J. Alzheimers Dis. 19, 691-704.
93. Plastino, M., Fava, A., Pirritano, D. et al. (2010) Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J. Neurol Sci. 288, 112-116.
94. Ponce-Lopez, T., Liy-Salmeron, G., Hong, E. and Meneses, A. (2011) Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3beta decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res. 1426, 73-85.
95. Prickaerts, J., Fahrig, T. and Blokland, A. (1999) Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. Behav. Brain Res. 102, 73-88.
96. Qiu, W. Q., Walsh, D. M., Ye, Z. et al. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273, 32730-32738.
97. Ramos-Rodriguez, J. J., Ortiz, O., Jimenez-Palomares, M. et al. (2013) Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology. 38, 2462-2475.
98. Reitz, C., Tang, M. X., Manly, J., Mayeux, R. and Luchsinger, J. A. (2007) Hypertension and the risk of mild cognitive impairment. Arch. Neurol. 64, 1734-1740.
99. Revsin, Y., Rekers, N. V., Louwe, M. C., Saravia, F. E., De Nicola, A. F., de Kloet, E. R. and Oitzl, M. S. (2009) Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Neuropsychopharmacology. 34, 747-758.
100. Roberson, M. R. and Harrell, L. E. (1997) Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Brain Res. Rev. 25, 50-69.
101. Roman, G. C. (2005) Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis. 20 Suppl 2, 91-100.
102. Russell, J. C. and Proctor, S. D. (2006) Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc. Pathol. 15, 318-330.
103. Sabbagh, M. and Cummings, J. (2011) Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 11, 21.
104. Salkovic-Petrisic, M. and Hoyer, S. (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J. Neural Transm Suppl. 217-233.
105. Salkovic-Petrisic, M., Knezovic, A., Hoyer, S. and Riederer, P. (2013a) What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J. Neural Transm. 120, 233-252.
106. Salkovic-Petrisic, M., Osmanovic-Barilar, J., Bruckner, M. K., Hoyer, S., Arendt, T. and Riederer, P. (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J. Neural Transm. 118, 765-772.
107. Salkovic-Petrisic, M., Osmanovic-Barilar, J., Knezovic, A., Hoyer, S., Mosetter, K. and Reutter, W. (2013b) Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin. Neuropharmacology. 77C, 68-80.
108. Salkovic-Petrisic, M., Tribl, F., Schmidt, M., Hoyer, S. and Riederer, P. (2006) Alzheimerlike changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J. Neurochem. 96, 1005-1015.
109. Santos, T. O., Mazucanti, C. H., Xavier, G. F. and Torrao, A. S. (2012) Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiol Behav. 107, 401-413.
110. Saxena, R., Voight, B. F., Lyssenko, V. et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 316, 1331-1336.
111. Schliebs, R. and Arendt, T. (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural Transm. 113, 1625-1644.
112. Schmatz, R., Mazzanti, C. M., Spanevello, R. et al. (2009) Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 610, 42-48.
113. Schrijvers, E. M., Witteman, J. C., Sijbrands, E. J., Hofman, A., Koudstaal, P. J. and Breteler, M. M. (2010) Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology. 75, 1982-1987.
114. Serrano-Pozo, A., Frosch, M. P., Masliah, E. and Hyman, B. T. (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 1, a006189.
115. Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. and Wolf, P. A. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 346, 476-483.
116. Sharma, B. and Singh, N. (2010) Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr Neurovasc Res. 7, 180-191.
117. Sharma, B. and Singh, N. (2011) Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl). 215, 677-687.
118. Sharma, M. and Gupta, Y. K. (2001) Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 68, 1021-1029.
119. Sharma, M. and Gupta, Y. K. (2002) Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 71, 2489-2498.
120. Shingo, A. S., Kanabayashi, T., Murase, T. and Kito, S. (2012) Cognitive decline in STZ-3V rats is largely due to dysfunctional insulin signalling through the dentate gyrus. Behav Brain Res. 229, 378-383.
121. Shoham, S., Bejar, C., Kovalev, E. and Weinstock, M. (2003) Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol. 184, 1043-1052.
122. Shonesy, B. C., Thiruchelvam, K., Parameshwaran, K. et al. (2010) Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiol Aging. 33, 430 e435-418.
123. Sonkusare, S., Srinivasan, K., Kaul, C. and Ramarao, P. (2005) Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci. 77, 1-14.
124. Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J. and Hyman, B. T. (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 25, 7278-7287.
125. Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C. L. and Ramarao, P. (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 52, 313-320.
126. Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R. and de la Monte, S. M. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J. Alzheimers Dis. 7, 63-80.
127. Stern, E. A., Bacskai, B. J., Hickey, G. A., Attenello, F. J., Lombardo, J. A. and Hyman, B. T. (2004) Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci. 24, 4535-4540.
128. Strachan, M. W., Reynolds, R. M., Frier, B. M., Mitchell, R. J. and Price, J. F. (2008) The relationship between type 2 diabetes and dementia. Br. Med. Bull. 88, 131-146.
129. Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K., Egan, J. M. and Mattson, M. P. (2008) Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309-317.
130. Tahirovic, I., Sofic, E., Sapcanin, A., Gavrankapetanovic, I., Bach-Rojecky, L., Salkovic-Petrisic, M., Lackovic, Z., Hoyer, S. and Riederer, P. (2007) Reduced brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus. Neurochem. Res. 32, 1709-1717.
131. Takeda, S., Sato, N., Uchio-Yamada, K. et al. (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. USA. 107, 7036-7041.
132. Teipel, S. J., Flatz, W. H., Heinsen, H. et al. (2005) Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain. 128, 2626-2644.
133. Tramontina, A. C., Wartchow, K. M., Rodrigues, L., Biasibetti, R., Quincozes-Santos, A., Bobermin, L., Tramontina, F. and Goncalves, C. A. (2011) The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats. J. Neural Transm. 118, 1641-1649.
134. Tuzcu, M. and Baydas, G. (2006) Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur. J. Pharmacol. 537, 106-110.
135. Urbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K. H., Duff, K., Stanley, H. E., Irizarry, M. C. and Hyman, B. T. (2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 99, 13990-13995.
136. Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R. and Selkoe, D. J. (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657-1665.
137. Walsh, D. M. and Selkoe, D. J. (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 44, 181-193.
138. Wang, T., Fu, F. H., Han, B., Zhang, L. M. and Zhang, X. M. (2011) Long-term but not shortterm aspirin treatment attenuates diabetes-associated learning and memory decline in mice. Exp. Clin. Endocrinol Diabetes. 119, 36-40.
139. Wang, X., Zheng, W., Xie, J. W., Wang, T., Wang, S. L., Teng, W. P. and Wang, Z. Y. (2010) Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol. Neurodegener. 5, 46.
140. Weedon, M. N. and Frayling, T. M. (2007) Insights on pathogenesis of type 2 diabetes from MODY genetics. Curr. Diab. Rep. 7, 131-138.
141. Weinstock, M., Kirschbaum-Slager, N., Lazarovici, P., Bejar, C., Youdim, M. B. and Shoham, S. (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. N Y Acad Sci. 939, 148-161.
142. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27, 1047-1053.
143. Wimo, A., Jonsson, L. and Winblad, B. (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord. 21, 175-181.
144. Woodhouse, A., West, A. K., Chuckowree, J. A., Vickers, J. C. and Dickson, T. C. (2005) Does beta-amyloid plaque formation cause structural injury to neuronal processes? Neurotox Res. 7, 5-15.
145. Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., Yu, X. and Gong, C. X. (2013a) Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J. Alzheimers Dis. 33, 329-338.
146. Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S. and Gong, C. X. (2013b) Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimers Dis. 37, 637-648.
147. Yao, J., Du, H., Yan, S. et al. (2011) Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J. Neurosci. 31, 2313-2320.
148. Zhang, M., Lv, X. Y., Li, J., Xu, Z. G. and Chen, L. (2008) The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp. Diabetes Res. 2008, 704045.
149. Zhang, S. and Murphy, T. H. (2007) Imaging the impact of cortical microcirculation on synaptic structure and sensory-evoked hemodynamic responses in vivo. PLoS Biol. 5, e119.
150. Zhao, W. Q., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A. and Klein, W. L. (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. Faseb J. 22, 246-260.